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Abstract
Background: The increase in life expectancy within the general population has resulted in an increasing number
of elderly adults, including patients with Down syndrome (DS), with a current life expectancy of about 50 years.
We evaluate the parameters of humoral and cellular immune response, the quantitative expression of the regulator
of calcineurin1 gene (RCAN1) and the production of cytokines. The study group consisted of adults DS (n = 24)
and a control group with intellectual disability without Down syndrome (ID) (n = 21) and living in a similar
environmental background. It was evaluated serology, immunophenotyping, the quantitative gene expression of
RCAN1 and the production of cytokines.
Results: In the DS group, the results showed an increase in NK cells, CD8, decreased CD19 (p < 0.05) and an
increase spontaneous production of IFNgamma, TNFalpha and IL-10 (p < 0.05). There was not any difference in
RCAN1 gene expression between the groups.
Conclusions: These data suggest a similar humoral response in the two groups. The immunophenotyping
suggests sign of premature aging of the immune system and the cytokine production show a proinflammatory
profile.
Introduction
The increase in life expectancy of the general population
has resulted in an increasing number of elderly adults,
including patients with Down syndrome (DS), with a
current life expectancy of about 50 years [1]. The death
causes in adults with DS are different from the ones of
the general population. Alzheimer’s disease (AD), conge-
nital heart defects, aspiration, pneumonia are among the
most frequent when compared to solid tumors and
ischemic heart disease [2-6]. The association with leuke-
mia decreases with age and it is not apparent after the
age of 40 [1]. Older DS have an increased susceptibility
to infections. However, most individuals with this syn-
drome do not show clear features of immunological dis-
eases. Many of these immunological alterations are age-
related changes and can be enclosed in the spectrum of
multiple signs of early senescence, which is characteris-
tic of the DS [7]. The immunological response varies in
the aging process. In children over the age of 6, the
absolute number of IgG and IgA increases. IgM rates
decrease in adolescence and throughout the aging pro-
cess, there is a low number of circulating B cells
(CD19), a decrease of CD4+, an increase of CD8 and
NK cells. In DS, granulocyte apoptosis is accelerated in
various conditions. T-cells with the early apoptotic phe-
notype were increased in cell cultures from DS children
[8,9]. The response against vaccinal antigens and other
antigens such as pertussis, rubella, measles, hepatitis A
and B was better in DS patients when compared with
other groups [10-14]. However other studies disagree
with this affirmation [15-18].
It was proposed a model suggesting that, in Down
syndrome, the overexpression of chromosome 21
encoded gene products leads to an impairment of the
immunological response [19]. However, there are few
studies about immunological parameters in older adults
with DS. This extra copy of HSA21 may be responsible
for the increased expression of many genes encoded on
this chromosome. The trisomy of chromosome 21 is
characterized by multiple signs of early senescence
which justify its inclusion within the group of
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genetic disorders in which multiple major aspects of the
senescent phenotype appear [20,21]. The regulator of
calcineurin 1 gene, RCAN1, is present in the specific
region in the HSA21 that was described as containing
the genes responsible for phenotypic characteristics of
the syndrome. The RCAN1 gene product interacts phy-
sically with calcineurin A, a catalytic subunit of the Ca
(2+)/calmodulin-dependent protein phosphatase PP2B
and inhibits its activity [22]. The dephosphorylation of
the nuclear factors of activated T cells (NFATs) by calci-
neurin is essential for activating cytokine gene expres-
sion and, consequently, the immune response. Although
t h ee f f e c t so fR C A N 1o nt h ei m m u n es y s t e mh a v en o t
yet been directly examined, the therapeutic benefits of
other calcineurin inhibitors have been examined in a
variety of conditions [23]. Current immunosuppressive
protocols are based mainly on the administration of the
calcineurin enzyme inhibitors cyclosporine A and FK506
[24]. The RCAN1 gene consists of seven exons, four of
which (exons 1-4) can be alternatively spliced to pro-
duce a number of different mRNA isoforms, since exons
5-7 are likely to be common in each mRNA isoform.
These isoforms may have different expression patterns,
functions and regulation mechanisms. The expression of
exon 2 was detected in fetal, but not adult, human brain
and calcineurin can induce the expression of RCAN1
isoform 4 mRNA, but it does not induce the other iso-
forms [25]. There is no study examining the quantitative
expression of RCAN1 in adults with DS and its associa-
tion with cytokines production. The purpose of this
study was to evaluate the aspects of humoral and cellu-
lar responses, as well as, to look into the quantitative
expression of the calcineurin1 (RCAN1) regulator with
relation to cytokine production in peripheral mononuc-
lear cells in adults with DS and the ones with intellec-
tual disabilities (ID) due to other causes and who were
monitored in the same institution, Associação de Pais e
Amigos dos Excepcionais (APAE-SP).
Results
1) Serology
The IgG, IgA, IgM, cRP, ASO frequencies and the com-
plement fraction (C3, C4) were similar in the serum of
both groups analyzed. Similarly, there were no difference
in the antibody levels against cytomegalovirus, mononu-
cleosis, toxoplasmosis and hepatitis B antigens, measles
and rubella vaccines (p > 0.05) (Table 1).
2) Immunophenotype
The CD3 and CD14 percentages were similar in both
groups. The results showed lower percentage of B lym-
phocytes (CD19+) in DS compared to ID individuals. In
contrast, higher percentages of CD8+ T cells; ratio CD4:
CD8 was (1:1) and NK cells were detected on DS com-
pared to ID individuals with significance difference (p <
0.05); (Table 2).
3) Cytokine production
The levels of IFNg,T N F a, IL-10 in the Down syndrome
group (DS) were higher than in the intellectual Disabil-
ities (ID) group (p < 0.05). The median value of IFNg
was 389.2 pg/ml in the Down syndrome group (DS) and
43.55 pg/ml in the Intellectual disabilities group (ID)
with p = 0.011. The TNFa had medians (DS and ID) of
131.2 pg/ml and 37.38 pg/ml, respectively, with p =
0.0071 and IL-2 had medians of 68.40 pg/ml in DS and
23.55 pg/ml in ID, with p = ns (Figure 1). The median
value of spontaneous IL-10 production was significantly
higher in the DS group (41.00 pg/ml) when compared
to the median value (11.10 pg/ml) in ID group with p =
Table 1 Serology in Down syndrome and intellectual
disabilities
Serology Down
syndrome(DS)
(%)
Intellectual
disabilities (ID) (%)
p
value*
IgG (mg/dl) 25 5 0.13
IgM, mg/dl 9 30 0.37
IgA, mg/dl 41 15 0.11
C3, mg/dl 35 50 0.49
C4, mg/dl 28 11 0.36
cRP, mg/l 21 52 0.06
ASO, UI/ml 64 33 0.07
Infectious monucleosis
(IgG), UA/ml
78 90 0.37
Toxoplasmosis(IgG),
UI/ml
35 60 0.29
HepatitisB (AntiHBS)
UI/ml
04 1
Measles (IgG), UI/ml 100 100 1
Rubella (IgG), UI/ml 71 89 0.36
Cytomegalovirus(IgG),
UI/ml
78 79 1
* Fisher test
Table 2 Phenotype of peripheral blood mononuclear cells
in Down syndrome and Intellectual disabilities
individuals
Imunophenotype Down syndrome
(DS) n = 19
Intellectual
disabilities(ID)
n=2 0
p
value*
CD3 69.77 ± 8.01 64.86 ± 10.53 0.11
CD4 40.96 ± 12.68 43.48 ± 11.00 0.51
CD8 34.38 ± 15.38* 22.47 ± 8.78* 0.005
CD19 3.63 ± 2.54* 15.28 ± 7.86* 0.001
CD16
+/CD56
+/CD3
- 44.75 ± 23.01* 29.19 ± 15.41* 0.017
CD14 77.88 ± 11.65 84.15 ± 9.987 0.078
*t test
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and ID) had spontaneous production of IL-4 and IL-5
with values below level of detection (< 20 pg/mL).
4) Relative Quantification of RCAN1 in PBMC
We studied the expression of RCAN1 in PBMC. The
data demonstrate neither negative regulation nor posi-
tive regulation of the gene RCAN1; with the medians of
(DS and ID) 1.05 and 1.08, respectively with p=n s ;
(Figure 3).
Discussion
In this study the humoral and cellular aspects of
immune response were evaluated, as well as the
quantitative expression of the RCAN1 gene in a sample
population of adults with DS and in an ID group with-
out Down syndrome with a similar environmental con-
d i t i o n .W es o u g h tt om i n i m i z et h ee x t e r n a la n d
environmental factors influences.
The results show the humoral and cellular immune
response aspects in adults with DS and with ID who were
followed at APAE-SP. Since all individuals in this study
live in the same community the immunological response
differences are not due to the environmental condition.
In this study, the humoral immune response of IgG,
IgM, IgA immunoglobulin isotypes, complement factor,
cRP, ASO, hepatitis B, cytomegalovirus, measles, rubella,
toxoplasmosis, mononucleosis were similar in both
groups. Some of the results are in line with the ones of
other authors [26,27,17,18] and they may reflect an
adaptive mechanism in adults with Down syndrome in
order to sustain an efficient response
The immunophenotypic findings in the DS group
show increased numbers of NK cells and CD8+ T lym-
phocyte subpopulation with a ratio of 1:1 CD4:CD8, and
decreased numbers of the B lymphocyte (CD19) percen-
tages suggesting a predominance of cells of the innate
immune response in DS [28]. Dietary antigens may
represent a continuous stimulus for the immune system
in this syndrome and interfere with normal immune
responses [29].
This data also suggest early immunosenescence and
accelerated apoptosis, preserving some subpopulations
[9]. Many of these alterations are similar to those char-
acteristic of chromosomally normal subjects of advanced
age [30].
The fetal thymic development in the trisomy 16
(Ts16) mouse was examined, which is considered to be
a model for human trisomy 21. The Ts16 thymus con-
tains 10 to 20% of the number of lymphocytes found in
a normal thymus at a comparable stage [31]. DS thymo-
cytes have a markedly diminished proportion of cells
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Figure 1 Spontaneous production of IFNg,T N F a and IL2 in
Down syndrome (DS) and Intellectual disabilities group (ID).
Periferic blood mononuclear cells were cultured for 48 h in
supplemented medium. IFNg, TNFa and IL2 were detected in the
supernatants by CBA. The results are expressed in pg/ml. *p < 0.05.
**p < 0.01.
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Figure 2 Spontaneous production of IL-10 in Down syndrome
(DS) and Intellectual disabilities group (ID). Periferic blood
mononuclear cells were cultured for 48 h in supplemented
medium. IL-10 was detected in the supernatants by CBA methods.
The results are expressed in pg/ml. ** p < 0.01.
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Figure 3 Relative quantification of RCAN1 in Down syndrome
(DS) and Intellectual disability group (ID). The median in two
groups (DS and ID) were respectively (1.05; 1.08) with p = ns.
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(alpha, beta TCR) and the associated CD3 molecule. In
addition, DS subjects had a lower proportion of CD4 +
CD45RA + cells representing naive T cells which have
recently emigrated from the thymus [32].
Clinical relevance of this finding is not well estab-
lished, considering that this immunophenotype is similar
to what is found in 26 centenarians [30].
The major age-related modifications were the follow-
ing: decreased absolute numbers of T lymphocytes (CD3
+), involving both CD4+ and CD8+ subsets, accompa-
nied by marked concomitant increased numbers of acti-
vated T cells (CD3+, HLA-DR+); marked decreased
numbers of B lymphocytes (CD19+) with increase in
some subclasses of immunoglobulin and an increase in
the number of cells with markers of NK activity [9,33].
Human immunosenescence represents a complex
remodeling of the immunological system and it is
induced by exposure to antigen and oxidative stress.
There was a deterioration of the clonotypical immunity,
while ancestral, innate immunity was largely preserved.
In an aging immune system, adaptive immunity deterio-
rates because of a progressive decline of naive T and B
cells and also due to a decrease of absolute numbers of
T and B lymphocytes. The innate compartment of the
immune system is relatively well preserved although
some age-dependent alterations can be also observed
[30]. Aging is characterized by a peculiar chronic
inflammatory status also called ‘inflammaging’, resulting
in cellular and molecular activation, that allows the
organism to respond to multiple stress present during
the process of aging [30,34].
These data suggest that there is an early immunose-
nescence probably due to accelerated apoptosis, preser-
ving some subpopulations [9,34,35].
Studies of the T-cell phenotype and function have fre-
quently resulted in conflicting outcomes, the overall evi-
d e n c es t r o n g l yp o i n t e dt oap r i m a r ya n dp r o f o u n d
impairment of T-cell mediated immunity [36].
Moreover, the relative and the absolute size of apopto-
tic CD3+ T lymphocytes, and the relative size of apopto-
tic CD19+ B lymphocytes were significantly higher in
DS children than in controls [9,36].
Several lines of evidence suggest that telomere short-
ening plays a causal role in cellular aging. If this were
true and if telomere shortening plays a role in cellular
aging, then one might predict critically shortened telo-
meres in the lymphocytes of these individuals. It was
found that, in DS, the rate of telomere loss in peripheral
blood lymphocytes was three times higher than that in
age-matched normal donors [37].
In this study the normal immunoglobulin level out-
comes, in spite of decreased CD19, indicate an adapta-
tive mechanism.
There are a very few studies about cytokines in DS.
Studies in children give evidence that the DS thymus
has lower number of phenotypically mature thymocytes,
which express high levels of the T cell receptor and
associated CD3-molecule [38].
Furthermore, there were high levels of tumor necrosis
factor (TNFa)a n di n t e r f e r o n( I F N g) cytokines that sug-
gest a deregulation in cytokine production in DS and it
may also provide an explanation for the abnormal thy-
mic anatomy and the thymocyte maturation [32]. In
adults, high percentages of IFNg (Th1) were found, and
the Th1/Th2 ratio was higher in DS patients than in
controls [39]. The elevated production of IFNg,T N F a
and IL-10 was not followed by IL-2 production that has
Th1 profile [40]. These cytokines’ production can be
likely due to the macrophage and to the NK cells and
are not produced by T cells.
The plasmatic high levels of pro-inflamatory cytokines
in DS patients are due to endothelial activation without
the activation of the immune responses [41,42]
There are a very few studies focused in cytokines pro-
duction in these populations, and none of them link the
production of cytokines to RCAN1’so v e r e x p r e s s i o ni n
peripheral blood mononuclear cells.
The overexpression of the RCAN1 gene has already
been observed in several tissues, particularly in the
human brain, the spinal cord, the kidney, the liver, the
mammary glands, the placenta, the skeletal muscles and
the heart. In adults, RCAN1 isoform 1 is most highly
expressed in the heart, the brain, the muscles and the
pancreas, while isoform 4 is most highly expressed in
the heart, the liver, the muscles, the placenta, the pan-
creas and the kidney. The expression of isoform 2 was
detected in fetuses [22,43,44]. The RCAN1 is involved
in the regulation of various cellular functions [23]. It is
overexpressed in the brains of DS fetuses and in post-
mortem brain samples of AD patients [20,44]. RCAN1
has also been implicated in cardiac valve formation and
in inhibition of cardiac hypertrophy [25]. RCAN1,
induced by VEGF, TNF-a, and calcium ionophore, par-
ticipates in the endothelial cell migration and in the
angiogenesis, showing the existence of several regulatory
mechanisms [45,46,28].
In this study we used a fragment that includes exon 5
to exon 7 which are present in all isoforms. There are
two hypotheses to relate phenotype to gene expression
in chromosome 21. Theoretically, the supernumerary
copy of human chromosome 21 (HSA21) is expected to
result in an increase in the level of transcripts of all
genes mapping to HSA21. However, it has been recently
observed that there is not always a direct correlation
between genomic imbalance (deletion or duplication)
and transcript level of genes within the aneuploid seg-
ment, suggesting that complex molecular mechanisms
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son, many studies have been trying to clear the mechan-
ism that leads to the expression of these genes [49]. A
study established that genes in chromosome 21,
expressed 1.5 times, would be superexpressed. In respect
to gene RCAN1, this finding concludes that an expres-
sion under 1.5 indicates that the gene has compensatory
mechanisms; in other words, it is influenced by or inter-
acts with other genes [50]. The findings in this study,
show that the RCAN1’s relative expression is about 1,
suggesting that the gene does not interfere in the DS
phenotype, which was studied in peripheral blood
mononuclear cells. Relative expression of RCAN1
showed neither positive nor negative regulation on the
calcineurin pathway and on the production of cytokines.
Maybe other ethics models of study would be neces-
sary with specific stimulus or which would be synergic
with other genes to demonstrate the overexpression of
RCAN1 in vivo.
Conclusion
T h e s ed a t as u g g e s tas i m i l ar humoral response in both
groups. In adults with Down’s syndrome, the immuno-
phenotypic alterations could be attributed the signals of
precocious immunosenescence in the immune system.
There is predominance of the Th1 profile in cytokines’
production without any apparent relation with the
RCAN1’s expression in the PBMC. The overexpression
of RCAN1 in PBMC was not observed. This study sti-
mulates the evaluation of new ways of studying these
genes according to the types of specific stimuli as well
as new ways of assessing the influence or interaction
with other genes.
Materials and methods
Population
The studied population included adults with Down syn-
drome (DS) or with intellectual disability but without
Down syndrome (ID), who were being followed at the
same Institution (Associação de Pais e Amigos dos
Excepcionais - APAE-SP), and who were living in a
similar environmental condition. The blood samples
were obtained from 24 patients (DS) with karyotype free
of trisomy and 21 patients (ID) without Down syndrome
confirmed by karyotype. Mean ages were 38 ± 8,7 years
for DS and 43 ± 8,3 years for ID. The collection proce-
dures were approved by the Heart Institute Ethics Com-
mittee (Heart Institute, Clinical Hospital, University of
São Paulo (HC-FMUSP). The selected patients and/or
those responsible for them were informed, in a clear
and detailed way, about the objectives of the research
and the procedures to be carried out, as well as about
the risks, discomforts and benefits, and they signed the
Terms of a free, prior and informed Consent.
Serology
The antibodies to hepatitis B (by MEIA), cytomegalo-
virus, infectious mononucleosis, toxoplasmosis, rubella
(by ELISA), measles (by IFI), and anti-streptolysin O
(ASO) were all investigated. the C-reactive protein
(cRP), the Complement factors C3, C4, (by nephelome-
try) and immunoglobulin isotypes IgG, IgM, IgA (by
immunoturbidimetric assay) present in the serum from
the individuals of the study were also investigated. All
serology was performed by the Central Laboratory of
Heart Institute, Clinical Hospital, University of São
Paulo.
Cellular Separation and Cell freezing
The venous blood was collected into heparinized tubes
(20 mL) and the separation of the peripheral blood
mononuclear cells (PBMC) was obtained with Ficoll-
Hypaque gradient [51]. A total of 4-5 × 10
6cells/ml were
frozen in appropriate volume of freezing media (10%
dimethyl sulphoxide - DMSO, and 90% fetal calf serum,
FCS) for posterior flow cytometry analysis.
Cellular Culture
Peripheral blood mononuclear cells (5 × 10
6 cells) were
cultured in DMEM (Sigma) containing 20% of fetal calf
serum (FCS). After 48 hours the culture supernatants
were collected to measure the cytokine production: IL-2,
IL-4, IL-5, IL-10, TNFa and IFNg.
Cytokine production
Cytokines in culture supernatants were quantified by
immunofluorescent flow cytometry (FASCalibur flow
cytometer, Becton Dickinson, California, USA) using
Human Chemokine and Th1/Th2 Cytokine Cytometric
Bead Array (CBA) reagent kits (BD Biosciences Phar-
mingen, California, USA) according to the manufac-
turer’s instructions. The production of IL-2, IL-4, IL-5,
IL-10, TNFa and IFNg cytokines was quantified. The
results were based on a standard concentration curve
established between 5000 and 20 pg/ml.
Flow cytometry analysis
The PBMC cells were thawed and washed for posterior
Flow cytometry analysis. The purified PBMC (4-6 ×
10
6cells) were incubated with a panel of fluorochrome-
conjugated mAbs. Cells were analyzed using anti-CD8
and andi-CD16-fluorescein isothiocyanate (FITC) (BD
Biosciences Pharmingen) anti-CD4, anti-CD19, anti-
CD14 and anti-CD56-phycoerythrin (PE) (BD Pharmin-
gen), anti-CD3-indotricarbocyanine coupled with
phycoerythrin (PE-Cy5) (BD Pharmingen) monoclonal
antibodies. Events (10 × 10
3) gated were analyzed using a
FACScalibur flow cytometer and CellQuest software
(Becton-Dickinson, Mountain View, CA). The population
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ally, based on the forward-scatter and side-scatter charac-
teristics. The relative count of each subpopulation was
expressed as a percentage within the total population.
Quantitative Real-Time PCR (QT-PCR) for RCAN1 gene
expression
Total RNA from PBMC was extracted using the Trizol
®
method (Life Technologies Inc., Grand Island, NY).
RNA quantities were determined by A260 measurement
and the integrity of the RNA was confirmed by gel elec-
trophoresis. One microgram of total RNA was used for
the cDNA synthesis. Briefly, 1 μg of total RNA total, 1
μl oligodT (500 μg/ml), 1 μld N T P( 1 0m Mo fd A T P ,
dCTP, dGTP and dTTP), DEPC water q.s.p. 12 μl, the
reaction was conducted for 5 min at 40°C. After this 4
μl Transcription Buffer 5x was added (Tris-HCl 250
mM pH 8,3, KCl 375 mM, MgCl2 15 mM), 2 μlD T T
0,1 M, 1 μli n h i b i t o rR N a s e( 4 0U / μl) (RNAse OUT™,
Invitrogen, Carlsbad, CA, EUA) and 1 μl Super-script
II™ Reverse Transcriptase (200 U/μL) (Invitrogen,
Carlsbad, CA, EUA), the reaction was heated for 50 min
at 42°C and 15 min at 70°C.
The sequences of primers for QT-PCR were designed
using Primer Express (PE Applied Biosystems, Foster City,
CA, USA). The following primer sequences were used:
RCAN1 (Acc. no. NM_203417) sense 5’-CAGTTTCT-
GATCTCCCCTCC-3’,a n t i - s e n s e5 ’-TCA-
TACTTTTCCCCTGGCCC-3’ and Glyceraldehyde-3-
phosphate dehidrogenase (GAPDH; Acc. no. M33197)
sense 5’-TGGTCTCCTCTGACTTCAACA-3’, anti-sense
5’-AGCCAAATTCGTTGTCATACC-3’.T h ep r i m e r
sequence design for the RCAN1 gene was performed cov-
ering exons 5, 6 and 7 which are constant in all the iso-
forms of the gene. Real-time PCR reactions were carried
out in an ABI Prism 7500 Sequence Detection system (PE
Applied Biosystems, Foster City, CA, USA). QT-PCR was
performed using the SYBR Green PCR Master Mix (PE
Applied Biosystems), according to the manufacturer’s
instructions. Quantities of specific mRNA in the sample
were measured according to the corresponding gene-speci-
fic standard curve. All the samples were tested in triplicate
with the reference gene GAPDH, a housekeeping gene for
normalization of data. For all genes we constructed stan-
dard curves and determined the slope to calculate the PCR
efficiency according to Pfaffl; (data not show) [52,53]. Nor-
malization and fold change were calculated with the ΔΔCt
method with GAPDH as the reference mRNA [54].
Statistical Analysis
Statistical analysis was performed by AlphPrism 3.0 and
SPSS 16 software. For continuous data with normal dis-
tribution, the impaired T test was used. For data which
do not include normal distribution, the Mann Whitney
test was used. For categorical data, the Fisher test or
Chi-square test were used. Statistical significance was
given for p < 0.05.
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